Skip to content
10-Q

Quarterly Report

VITASPRING BIOMEDICAL CO. LTD.

0001640334-26-001083

← back to feed
Filed
Jun 17, 2026 12:14 PM ET
Period of report
Jun 17, 2026

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2027 · Jun 17, 2026 207.03M sh
Shares Diluted Q1 2027 · Apr 30, 2026 207.03M sh
Shares Diluted Q1 2027 · Apr 30, 2025 207.03M sh
Operating Cash Flow Q1 2027 · Apr 30, 2026 $6.08K
Operating Cash Flow Q1 2027 · Apr 30, 2025 −$787
Stockholders Equity Q1 2027 · Apr 30, 2026 −$4.51M
Stockholders Equity Q1 2027 · Jan 31, 2026 −$4.43M
Stockholders Equity Q1 2027 · Apr 30, 2025 −$4.1M
Stockholders Equity Q1 2027 · Jan 31, 2025 −$4.02M
Current Liabilities Q1 2027 · Apr 30, 2026 $4.52M
Current Liabilities Q1 2027 · Jan 31, 2026 $4.45M
Total Liabilities Q1 2027 · Apr 30, 2026 $4.52M
Total Liabilities Q1 2027 · Jan 31, 2026 $4.45M
Current Assets Q1 2027 · Apr 30, 2026 $9.77K
Current Assets Q1 2027 · Jan 31, 2026 $10.53K
Total Assets Q1 2027 · Apr 30, 2026 $11.43K
Total Assets Q1 2027 · Jan 31, 2026 $14.68K
Eps Diluted Q1 2027 · Apr 30, 2026 $0.00
Eps Diluted Q1 2027 · Apr 30, 2025 $0.00
Sga Expense Q1 2027 · Apr 30, 2026 $75.84K
Sga Expense Q1 2027 · Apr 30, 2025 $69.15K
Net Income Q1 2027 · Apr 30, 2026 −$75.84K
Net Income Q1 2027 · Apr 30, 2025 −$80.54K
Operating Income Q1 2027 · Apr 30, 2026 −$75.84K
Operating Income Q1 2027 · Apr 30, 2025 −$69.15K
Revenue Q1 2027 · Apr 30, 2026 $0
Revenue Q1 2027 · Apr 30, 2025 $0